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Introduction: T cells play an important role in the pathogenesis of systemic lupus erythematosus (SLE). Clonal
expansion of T cells correlating with disease activity has been observed in peripheral blood (PB) of SLE subjects.
Recently, next-generation sequencing (NGS) of the T cell receptor (TCR) β loci has emerged as a sensitive way to
measure the T cell repertoire. In this study, we utilized NGS to assess whether changes in T cell repertoire diversity
in PB of SLE patients correlate with or predict changes in disease activity.
Methods: Total RNA was isolated from the PB of 11 SLE patients. Each subject had three samples, collected at
periods of clinical quiescence and at a flare. Twelve age-matched healthy controls (HC) were used for reference.
NGS was used to profile the complementarity-determining region 3 (CDR3) of the rearranged TCR β loci.
Results: Relative to the HC, SLE patients (at quiescence) demonstrated a 2.2-fold reduction in repertoire
diversity in a given PB volume (P <0.0002), a more uneven distribution of the repertoire (Gini coefficient, HC
vs SLE, P = 0.015), and a trend toward increased percentage of expanded clones in the repertoire (clone size >1.0 %,
HC vs SLE, P = 0.078). No significant correlation between the overall repertoire diversity and clinical disease activity
was observed for most SLE patients with only two of eleven SLE patients showing a decreasing trend in repertoire
diversity approaching the flare time point. We did not observe any overlap of CDR3 amino acid sequences or a
preferential Vβ or Jβ gene usage among the top 100 expanded clones from all SLE patients. In both HC and SLE, the
majority of the expanded clones were remarkably stable over time (HC = 5.5 ±0.5 months, SLE = 7.2 ±2.4 months).
Conclusions: A significant decrease in T cell repertoire diversity was observed in PB of SLE patients compared to HC.
However, in most SLE patients, repertoire diversity did not change significantly with increases in disease activity to a
flare. Thus, without a priori knowledge of disease-specific clones, monitoring TCR repertoire in PB from SLE patients is
not likely to be useful to predict changes in disease activity.Introduction
Systemic lupus erythematosus (SLE) is a prototypic auto-
immune disorder with complex etiology, diversity of
clinical manifestations, and an unpredictable disease
course. T cells play an essential role in SLE pathogenesis
[1–5]. Clonal expansion of T cells have been observed in
SLE patients’ peripheral blood (PB) [6–12] and various* Correspondence: Ann.Ranger@biogenidec.com
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as nucleosomal histones [2, 18] and U1 small nuclear ribo-
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result of T cell depletion [28]. Taken together, these
studies suggest a crucial role for T cells in the patho-
genesis of SLE.
Ninety-five percent of T cells in the blood express T
cell receptor (TCR) consisting of heterodimers of αβ
chains [29]. TCRβ chains are assembled by combinator-
ial somatic recombination events that splice together the
variable (V), diversity (D), and joining (J) gene segments
(VDJ) [29]. This junctional region of the TCR chains,
also known as the complementarity-determining re-
gion 3 (CDR3), is highly diverse and is an important
determinant of antigen recognition by T cells. Because
allelic exclusion leads to the expression of only one
TCR chain in mature T cells [29], each unique CDR3
sequence is a proxy for T cell clonotype. Thus, analysis
of TCR CDR3 sequences has provided a useful means
to study clonal expansions, repertoire breadth, and
other properties such as CDR3 length polymorphisms,
V(D)J gene usage, and sequence specificity of the T cell
response.
Prior studies examining the expansion and diversity of
the TCR repertoire in SLE have used reverse transcriptase-
polymerase chain reaction (RT-PCR) of the TCRβ CDR3
region followed by techniques such as Southern blots [13,
14], CDR3 spectratyping [11] and immunoscope analysis
[6, 9], single-strand conformation polymorphism (SSCP)
[10, 13], or laborious cloning and sequencing analysis of se-
lect bands (or peaks) [6–8, 12, 14, 15]. Several interesting
observations have come out of these studies, such as clonal
expansions and reduction of the TCRβ repertoire diversity
in PB [6, 7, 9, 11], correlation of PB T cell expansions
[8, 10] or spectratype skewing [6] with disease activity,
and the abundance of clonally expanded T cell popula-
tions in skin lesions [13] and kidneys [14–16] with
concomitant detection of overlapping clones in PB [15]
or not [13, 14, 16]. The immensity of T cell diversity
presents a formidable challenge to its study and the
aforementioned techniques lack sufficient depth of
coverage (ability to detect low-frequency clones) and
resolution (lack of sequence information without add-
itional cloning steps). The advent of next-generation
sequencing (NGS) has provided a means to exhaust-
ively sequence and accurately quantify the relative
abundance of TCR sequences within a given sample in
a high-throughput manner. Consequently, NGS has
become a powerful tool in the study of immune reper-
toire with potential applications in the identification
and tracking of pathogenic clones, monitoring immune
status and disease activity, and immune reconstitution
following therapeutic interventions.
Disease flares in SLE patients are a challenge to clin-
ical management as they are difficult to predict. The
objective of this study was to use NGS to perform alongitudinal analysis of the T cell repertoire in blood
from SLE patients prior to and at an increase in clinical
disease activity. The CDR3 region of the TCRβ chain
was sequenced from the blood of 11 SLE patients over
three visits each, representing clinical quiescence, pre-
flare, and flare stages. We defined flare as an increase in
SLE disease activity index (SLEDAI) ≥4 and/or an in-
crease in the Physician Global Assessment (PGA) of ≥1.
Twelve healthy controls (HC), including six subjects
with PB collected at two longitudinal time points, were
included for comparison. Our findings show a signifi-
cant reduction in T cell repertoire diversity in SLE pa-
tients compared to HC. However, in most cases, an
increase in SLE disease activity leading to a flare was
not accompanied by significant changes in the TCR
repertoire diversity.
Methods
Patient selection and controls
All SLE subjects were selected from an observational
study, the Study of biological Pathways, disease Activity
and Response markers in patients with systemic lupus
Erythematosus (SPARE). The study was approved by the
Johns Hopkins University School of Medicine Institu-
tional Review Board. SLE patients were enrolled from
the Hopkins Lupus Cohort following informed consent.
Adult patients were eligible if they were aged 18 to
75 years old and met the definition of SLE as defined by
the revised American College of Rheumatology classifi-
cation criteria [30, 31]. All patients were evaluated by
the same physician at entry and all subsequent cohort
visits (MP). Three longitudinal samples were selected
from 11 female SLE patients. One sample was chosen at
clinical flare, defined as an increase in Safety of Estro-
gens in Lupus Erythematosus National Assessment
(SELENA) SLEDAI from the preceding visit by ≥4 (max-
imum increase = 18) and/or an increase in PGA of ≥1.0
(maximum increase = 2.0). For each SLE subject, two
samples were chosen at visits with no clinical activity as
defined by SELENA SLEDAI <2 (low complement or
double-stranded DNA (dsDNA) only) and/or PGA ≤0.5.
The visit immediately preceding the flare was defined as
pre-flare. The average duration from quiescence to flare
was 7.2 ±2.4 months (± standard deviation (SD), range of
4.6 to 13.8 months) whereas the average duration between
any consecutive sample points was 3.6 ±1.9 months. The
severity of the flare for the 11 SLE patients was varied.
Using the following SLEDAI-based stratification (0 = no
increase, 1 to 5 = mild, 6 to 10 = moderate, 11 to 19 =
high, and ≥20 = very high) [32], only one of eleven flared at
a high level, seven of eleven at moderate level, and two of
eleven at mild level. One patient (SLE7) exhibited no in-
crease in SLEDAI score at flare, but was selected based on
an increase in PGA from 0 to 1.5. Organ involvement
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3), and skin (n = 4). All patients were taking immunosup-
pressant(s) and/or antimalarial drugs (hydroxychloroquine)
at the time samples were obtained. The demographic and
clinical characteristics of these patients are summarized in
Table 1. Twelve age- and race-matched healthy female vol-
unteers were included as HC (from Bioreclamation LLC,
Hicksville, NY, USA and the Biogen blood donor program






SLE1/white Quiescent 0 0 2
Pre-flare 4 0 0
Flare (skin) 6 1.5 10
SLE2/white Quiescent 0 0 2
Pre-flare 3 0.5 2
Flare (skin) 5 2 10
SLE3/white Quiescent 0 0.5 2
Pre-flare 5 0.5 2
Flare (skin) 7 2 10
SLE4/white Quiescent 0 0 0
Pre-flare 3 0 0
Flare (joint) 6 1.5 4
SLE5/white Quiescent 0 0 0
Pre-flare 3 0 0
Flare (renal) 7 1.5 10
SLE6/black Quiescent 0 0 0
Pre-flare 3 0.5 0
Flare (renal) 6 1.5 4
SLE7/black Quiescent 0 0 0
Pre-flare 3 0 0
Flare (joint) 14 1.5 0
SLE8/white Quiescent 0 0 0
Pre-flare 4 0 0
Flare (skin) 7 1 18
SLE9/black Quiescent 0 0 0
Pre-flare 3 0 0
Flare (renal) 9 1.6 6
SLE10/black Quiescent 0 0.5 2
Pre-flare 4 0.5 0
Flare (renal) 6 2.5 6
SLE11/white Quiescent 0 0.5 0
Pre-flare 3 0 0
Flare (joint) 7 1.5 6
All subjects were female. Reference ranges, WBC: 4.5 to 11 x103/uL; C3: 79 to 152 m
azathioprine; C3, complement component 3; C4, complement component 4, dsDNA
mycophenolate mofetil; PGA, Physician Global Assessment; Pred, prednisone; SLEDAHC subjects, two longitudinal samples (average duration =
5.5 ±0.5 months) were analyzed.
RNA isolation and cDNA synthesis
Total RNA was isolated from PAXgene preserved PB
using the PAXgene blood RNA kit (PreAnalytiX, Franklin
Lakes, NJ, USA). cDNA was prepared from 500 ng of total
RNA using the high-capacity cDNA reverse transcription
kit (Applied Biosystems, Foster City, CA, USA).WBC
(103/mm3)
C3 (mg/dl) C4 (mg/dl) Anti-dsDNA
(U/ml)
Therapy
3.93 146 22 40 MMF/HCQ
3.82 108 19 0 MMF/HCQ
4.34 115 21 80 MMF/HCQ
5.6 85 2 0 Pred/MMF
5.5 88 3 0 Pred/MMF
7.8 105 4 0 Pred/MMF
6.26 86 11 0 Pred
7.04 86 11 0 Pred
4.53 85 11 0 Pred
6.44 96 21 0 Pred/AZA
8.13 106 22 0 Pred/AZA
7.96 102 22 0 Pred/AZA
2.68 108 21 0 MMF/HCQ
1.78 98 17 0 MMF/HCQ
1.85 81 13 40 MMF/HCQ
13.35 134 19 0 Pred/HCQ
9.16 135 26 0 HCQ
10.35 121 21 0 HCQ
5.3 134 35 0 AZA/HCQ
6.3 139 38 0 AZA/HCQ
4.4 145 40 0 AZA/HCQ
5.53 106 21 0 HCQ
5.83 97 17 0 HCQ
4.72 94 18 0 HCQ
5.75 161 39 0 Pred/MMF
5.83 145 29 0 Pred/MMF
7.08 186 29 0 Pred/MMF
7.3 144 60 0 Pred/HCQ
6.93 90 38 0 Pred/HCQ
6.62 97 43 0 Pred/HCQ
7.26 146 27 0 Pred/LFM
7.14 132 33 0 Pred/LFM
7.18 139 26 0 Pred/LFM
g/dL; C4: 14 to 42 mg/dL; dsDNA titer <10 considered negative. AZA,
, double-stranded DNA; HCQ, hydroxychloroquine; LFM, leflunomide; MMF,
I, SLE disease activity index; WBC, white blood cell
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NGS was performed using the immunoSEQ platform
(Adaptive Biotechnologies, Seattle, WA, USA), and the
methodology used has been validated and detailed before
[33]. Briefly, the CDR3 region of the TCRβ loci was
amplified from cDNA using PCR primers specific for all
Vβ and Jβ genes annotated in the IMGT database [34],
barcoded, and deep-sequenced using the Illumina HiSeq
platform (Illumina, San Diego, CA, USA). Repertoire di-
versity was assessed using clonality scores, which is de-
rived from Shannon’s entropy [35]. Shannon’s entropy
quantifies the uncertainty in predicting the sequence
identity of a random sequence from a dataset. To allow
for comparisons between samples differing in the total
number of reads, entropy was normalized by division of
log 2 of the number of unique productive sequences.
Clonality is the reciprocal of normalized Shannon’s en-
tropy with values ranging from 0 (most diverse) to 1 (least
diverse). Gini coefficient, commonly used as a measure of
income inequality in economics, was used to assess the in-
equality of clonotype distribution within a repertoire [36].
The Lorenz curve was derived by plotting the cumulative
proportion of total sequences on the y-axis relative to con-
tribution by unique clonotypes on the x-axis. Gini coeffi-
cient, defined as the ratio of the area between the line of
equality (45 degree line) and the Lorenz curve to the area
under the line of equality, was calculated using the trapez-
oidal area method [37]. Gini coefficient value ranges from
0 representing equal frequency of all clonotypes in the
repertoire to 1 representing a monoclonal sample.
Statistical analysis
Statistical analysis was performed using GraphPad Prism
v.6 (GraphPad Software, San Diego, CA, USA). Non-
parametric comparisons between groups were performed
using Mann–Whitney test (two groups), and between
paired samples using Wilcoxon (two groups) or Friedman
test (three groups). Mean values were compared using t test.
Correction for multiple testing was performed using false
discovery rate (FDR) set to 10 %. P <0.05 was considered
significant. Motif analysis was performed using HOMER
DNA motif analysis software [38], using the top 100 CDR3
sequences from SLE patient samples as query and the top
100 CDR3 sequences from HC as background. Significantly
expanded or contracted T cell clones across longitudinal
samples were defined by using DEseq R package to train a
model of T cell repertoire dispersion over time using the
HC samples and then applied to all samples with a P value
cutoff of 0.001, as previously described [39, 40].
Results
Patient summary
The demographic and clinical characteristics of the 11
female SLE patients are summarized in Table 1. Patientselection criteria are described in Methods. For compara-
tive analysis, 12 female HC were included in this study.
There was no significant difference in age between the
two groups (years ±SD of 42.2 ±9.0 (HC) vs 46.1 ±7.9
(SLE), P = 0.291). Racial composition was 67 % white and
33 % black in HC vs 63 % white and 37 % black in SLE.
All SLE subjects were receiving treatment.
TCR repertoire diversity and clonal expansions in HC and
SLE subjects
Deep level sequencing of the TCRβ CDR3 region from
PB of 23 subjects (51 samples) produced an average of
6,472,081 total and 317,535 unique productive reads
(Table S1 in Additional file 1). First, we wanted to assess
any groupwise differences in repertoire diversity between
HC and SLE. Only patient samples corresponding to dis-
ease quiescence were utilized for this comparison with
HC. Because each unique CDR3 sequence denotes a T
cell clonotype, we assessed quantitative difference in the
number of uniques between HC and SLE. We found that
the number of uniques when normalized to a fixed blood
volume was 2.2-fold lower in treatment-experienced SLE
subjects compared to HC subjects (P = 0.0023, Fig. 1a).
Using Gini coefficient, we also found a significant trend to-
ward a more skewed clonotype distribution (higher values)
in SLE compared to HC (P = 0.0151, Fig. 1b). Thus, for a
given volume of PB, SLE repertoire is significantly dimin-
ished in diversity and skewed in its distribution.
Next, we wanted to assess the relative degree of clonal
expansions within the repertoire of these two groups.
The size of each clone was calculated based on its fre-
quency in the repertoire. Scatterplots of all clones >0.01 %
are shown in Fig. 1c (HC) and Fig. 1d (SLE). There was no
significant difference in the percentage of clones in the
repertoire that were >0.01 % (P = 0.060), >0.1 % (P =
0.406), or >1.0 % (P = 0.078) between HC and SLE, al-
though SLE subjects consistently showed a higher per-
centage of these clonally expanded populations (Fig. 1e).
When the cumulative contribution by the top 500
clones to the total repertoire was analyzed, we found
disproportionately larger contribution by just the top 50
clones (Figure S1 in Additional file 2). We therefore
placed the clones into three groups based on their size -
the top 50 clones, >95th percentile, and <95th percentile
for comparative analysis (Fig. 1f ). There was no signifi-
cant difference in the percent contribution to the reper-
toire by the top 50 clones between HC and SLE subjects
(average percent of repertoire ±SD of 10.85 ±6.75 (HC)
vs 13.62 ±12.37 (SLE), P = 0.913) or by the >95th
percentile group (average percent of repertoire ±SD of
43.21 ±6.81 (HC) vs 44.77 ±11.29 (SLE), P = 0.913).
Thus, in both HC and SLE groups, the top 5th percentile





Fig. 1 Analysis of T cell receptor (TCR) repertoire of healthy controls (HC) and systemic lupus erythematosus (SLE) patients. a Repertoire diversity
as measured by the number of clonotypes per normalized blood volume, HC vs SLE (Mann–Whitney test). b Evenness of clonotype distribution
using Gini coefficient, HC vs SLE (Mann–Whitney test). c and d Scatterplot of clonotypes exceeding >0.01 % clonal size of the total reads, for
HC (C) and SLE (D). Clonal size >1 % (red horizontal line) designates highly expanded clones (HEC). e Frequency distribution of clones by size
difference between HC and SLE. Mean values with error bars representing + standard deviation (SD) are plotted for clonal sizes >0.01 %, >0.1 %,
and >1.0 % (Mann–Whitney test). f Proportion of total repertoire occupied by clonal groups defined by the top 50, the >95th percentile and the
<95th percentile of clones. Mean values with error bars representing ±SD are shown. HC vs SLE; top 50 clones group, P = 0.913, >95th percentile
group, P = 0.913 (Mann–Whitney test)
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been reported in PB [6] or intrarenal T cells [14], while
other studies have shown no such preference in PB [8, 10].
We calculated the frequency of Vβ and Jβ gene usage as a
percentage of uniques to avoid bias from expanded clones.
We found differential usage of four Vβ genes: V05-04,
V05-05, V05-06, V21-01 (HC vs SLE, all comparisons
P <0.05, FDR = 10 %) and four Jβ genes: J01-02, J01-04,
J01-05, J02-01 (HC vs SLE, all comparison P <0.05,
FDR = 10 %) (Figure S2 in Additional file 2). To ac-
count for potential contribution of race to these results,
groupwise comparison of gene usage was performedbetween whites and blacks. None of the genes were dif-
ferentially expressed by race.
Longitudinal evaluation of the TCR repertoire in HC and
SLE subjects
To investigate the differences in repertoire diversity
during increase in clinical disease activity, we looked at
longitudinal samples representing quiescence, pre-flare,
or flare status for all 11 SLE patients over an average
duration of 7.2 months (range, 4.6 to 13.8 months). For
reference, six HC repertoires were analyzed over an
average period of 5.5 months (range, 5 to 6 months).
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between the time points for each subject are shown in
Fig. 2 (for SLE) and Fig. 3a (for HC). The top 50 clones
were highly stable with 73 % (eight of eleven) of SLE
and 67 % (four of six) of HC subjects showing no
addition or subtraction of clones over time. A single clo-
notype addition into the top 50 repertoire was seen in
18 % (two of eleven) of SLE and 33 % (two of six) of HC.
Only one of eleven (9 %) SLE subjects (SLE3) showed
















Fig. 2 Longitudinal analysis of T cell receptor (TCR) repertoire in systemic l
ranks of the top 50 clones in SLE. The three time points in SLE patients rep
(months) from the first sample are indicated. Clones above the horizontal rtime point (Fig. 2). The amino acid sequence, rank, and
frequency of the top 50 clones in the repertoire are
summarized in Table S2 in Additional file 1 for HC and
Table S3 for SLE.
Several other observations stand out with regard to
clonal expansions in PB. We find that most repertoires
are dominated by only a few clones whose abundance
and rank is maintained over time. Using clone size >1 %
as a reference for highly expanded clones (HEC), a term
coined by Klarenbeek et al. [41], 73 % (eight of eleven)upus erythematosus (SLE) patients. Clonotype frequency and relative
resent quiescence (Q), pre-flare (PF) and flare (F). The elapsed time
















Fig. 3 Longitudinal analysis of T cell receptor (TCR) repertoire in healthy control (HC) subjects and comparisons with systemic lupus erythematosus
(SLE) patients. a Clonotype frequency and relative ranks of the top 50 clones in HC. The elapsed time (months) from the first sample are indicated.
Clones above the horizontal red line (>1 %) denotes highly expanded clones (HEC). b and c Analysis of clonality (b) and Gini coefficient (c)
values in longitudinal samples from HC and SLE patients. No significant trends for clonality or Gini coefficient values were observed within
either HC or SLE samples (HC, paired analysis using Wilcoxon test; SLE, paired test using Friedman test). Only patients SLE1* and SLE6**
exhibited an increase in clonality (decreasing diversity) at clinical flare. Longitudinal data points from each individual are connected by a line
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in their repertoire (Fig. 2). However, HECs can also be
seen in HC where 33 % (two of six) subjects (HC166 and
HC169) showed clones >1 % in their repertoire (Fig. 3a).
Thus HEC is not a feature unique to SLE and can also be
observed in HC. Next, using clonality as a measure of rep-
ertoire diversity, we assessed how the overall T cell diver-
sity in patients changes during increase in disease activity
to a flare. Clonality scores showed a wide distribution of
values between subjects within both groups (Fig. 3b).
However, within each subject, no significant changes in
clonality were seen in longitudinal samples from either
HC (P = 0.312) or SLE groups (P = 0.976). Only two of
eleven SLE subjects (SLE1 and SLE6, marked as * and ** in
Fig. 3b) showed increasing clonality (corresponding to de-
creasing diversity) going from disease quiescence to flare.
Next, we used Gini coefficient to look at changes in the
evenness of clonal distribution of the repertoire over time.
No significant changes in Gini coefficient were seenbetween longitudinal samples of HC (P = 0.687) or SLE (P
= 0.843) subjects (Fig. 3c), although Gini coefficient dif-
fered significantly between the two groups (Fig. 1b). In
order to assess whether increased clonal expansion oc-
curred during flare, we also looked at changes in the rela-
tive contribution to the total repertoire by the three
groups of clones stratified by size (the top 50, >95th per-
centile, and <95th percentile). No significant difference in
contribution to the total repertoire by these three groups
of clones was seen in longitudinal samples from SLE (Fig-
ure S3 in Additional file 2) or HC subjects (Figure S4 in
Additional file 2). Again, when analyzed individually, the
exceptions were two SLE subjects (SLE1 and SLE6) who
showed a steady increase in the percentage of repertoire
contributed by the top 50 and the >95th percentile group
(Figure S3 D and E in Additional file 2) mirroring the
clonality results (Fig. 3b).
Finally, we investigated the expansion and contraction
of T cell clonal lineages between quiescent and flare
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pairs of HC samples. Clones were identified as expanded
or contracted if their abundance in the flare sample was
different from their abundance in the quiescent sample
at P <0.001 using a DEseq differential abundance model
trained on the six HC pairs (see Methods). We found a
median of 15 (range 0 to 165) expanded clones and 9
(range 4 to 23) contracted clones in the HC pairs, and a
median of 9 (range 0 to 114) expanded clones and 2
(range 0 to 19) contracted clones in the SLE sample
pairs; thus, the clonal dynamics revealed by a differential
abundance analysis do not support an excess in the
clonal expansion of T cell lineages in SLE patients from
quiescence to flare compared to HC sampled at similarA
B
Fig. 4 Analysis of primary structure of T cell receptor (TCR) β complementa
by expanded clones (size >0.1 %) from systemic lupus erythematosus (SLE)
each clone. None of the CDR3 amino acids sequences were overlapping. b
points as a proportion of unique reads or total reads in healthy controls (H
deviation (SD) are shown (Mann–Whitney test)time points. Together, these data suggest that in SLE
subjects, increase in clinical disease activity is not always
accompanied by overt expansion of T cell clones and
concomitant decrease in repertoire diversity in the
blood.
CDR3 sequence diversity of dominant clones from SLE
patients
Next, we wanted to address whether clonally expanded
T cells in SLE shared any common structural features
between patients. We found great heterogeneity and min-
imal overlap in the use of Vβ and Jβ gene by the top clones
(>0.1 % by size) from the 11 SLE repertoires (Fig. 4a).
Where the Vβ and Jβ gene usage overlapped, the aminority-determining region 3 (CDR3) sequences. a Vβ and Jβ gene usage
patients. The area of each bubble corresponds to the relative size of
The amount of sequences that overlap in the repertoire across time
C) and SLE patients. Mean values with error bars depicting + standard
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did not find any overlap in the amino acid sequences of
the top 100 clones (which is a more encompassing list than
that generated by >0.1 % size criteria) between any SLE pa-
tients. Similarly, no overlap was seen for the top 100 clones
in HC subjects. This is in agreement with prior studies in
SLE blood showing no CDR3 amino acid sequence overlap
of the expanded T cell clones between subjects [6, 8]. Next,
using the HOMER motif-finding module, no amino acid
motifs were found to be significantly enriched in the top
100 productive sequences from SLE when compared to
HC as the background dataset.
Finally, we addressed the idea that the SLE repertoire
may be under selective pressure to maintain autoantigen-
reactive clones and consequently, might display a higher
proportion of clones that are maintained over time
when compared to HC. We found in SLE patients that
19.1 ±4.9 % of clones were shared over time account-
ing for 51.7 ±13.9 % of the total repertoire, which was
not significantly different from HC where 16.8 ±2.4 %
of clones were shared over time and accounted for
49.9 ±7.1 % of the total repertoire (HC vs SLE, P =
0.333 for unique reads and P = 0.767 for total reads,
Fig. 4b). In this comparison, the average time between
the two sample points for SLE was 4.02 ±2.69 months
and for HC was 5.47 ±0.17 months. Thus, compared to
HC, SLE repertoire did not display a significantly
higher level of clones that were maintained in the rep-
ertoire over a similar time period.
Discussion
One of the key unmet needs in SLE clinical management
are biomarkers predictive of flare. It has been well
established that T cells play a critical role in the under-
lying pathogenesis of SLE. Thus, in this study we asked
whether changes in the T cell repertoire in the blood of
SLE patients as measured by NGS could yield important
information about the underlying disease process and
potentially serve as a biomarker of disease activity. Pub-
lished work assessing T cell repertoire in SLE patients
has mainly relied on approaches such as Southern blots
[13, 14], SSCP analysis [10, 13], and conventional spec-
tratyping [6, 9, 11], which can broadly inform on the V
(or J) gene-level usage but requires additional PCR cloning
and sequencing steps [6–8, 14, 15] to achieve clonotype-
level resolution. Comprehensive assessment of the T cell
repertoire entails knowing both the diversity (the number
of unique clonotypes) and the relative abundance of these
clonotypes (number of reads per clonotype), which can be
obtained simultaneously by NGS using genomic DNA
(gDNA) or mRNA templates. Although differences in
TCRβ mRNA quantity per cell exist [42, 43], clonal rank
derived from mRNA abundance correlates well with those
quantified from sorted cell population [42, 44] or itscorresponding gDNA [45]. Therefore, in this study we
used mRNA extracted from blood to evaluate the T cell
repertoire of HC and SLE subjects.
Previous studies have shown a higher number of ex-
panded T cell clones in the PB of SLE subjects during
active disease [6–8, 10, 11]. While we also found ex-
panded clones in SLE patients, their number and relative
size, in most cases, did not significantly increase prior to
or during a clinical flare. Several differences in study
design, the benefits of NGS notwithstanding, should be
noted. The degree of disease activity for most patients in
our cohort was moderate (SLEDAI = 6 to 10) with only
one patient (SLE8) exhibiting high (SLEDAI = 11 to 19)
activity during flare and only two patients (SLE1, SLE5)
with a measurable anti-dsDNA antibody titer in serum
(Table 1). The study by Kato et al. [8] used cloning and
sequencing of only three TCRβ families (5S1, 8, 14) to
track clonal expansion and found an increase in the pro-
portion of expanded clones in one subject from 24 % to
79 % of total sequences (pre-flare to flare, SLEDAI in-
crease from 4 to 11, anti-dsDNA antibody titer at flare
approximately 90 IU/ml). No differences in clonal ex-
pansions were seen between times pre- and post-flare. In
another study, three patients treated only with prednis-
olone (Pred) showed a correlation between the number
of expanded T cell clones and SLEDAI (with SLEDAI
values ranging from 15 to 21 during disease activity and
between 2 and 5 during disease inactivity in these sub-
jects) [10]. In this study, the number of distinct bands
from SSCP blots was used to indicate clones, however,
the homogeneity of such bands or spectratype peaks [6]
cannot be assumed without further sequencing. In other
studies, cross-sectional comparisons of patients with
inactive vs active disease were used to arrive at similar
conclusions [7, 9, 11]. Using improved sensitivity of NGS,
we find that in most SLE subjects (nine of eleven), flaring
to moderate disease activity level was not associated with
an increase in clonal expansion or a decrease in overall
repertoire diversity. All SLE subjects, with one exception
(SLE8), were being treated with immunosuppressants and
this could affect the clonal expansion of T cells. However,
for each patient, medication was constant between periods
of pre-flare and clinical flare and if T cell clonal expan-
sion was key to the increased clinical activity, it should
be observed despite treatment. The two patients where
increased clinical activity was associated with clonal ex-
pansions presented with diverse backgrounds. SLE1 was
a white female presenting with a cutaneous flare, on
hydroxychloroquine (HCQ) and mycophenolate mofetil
(MMF) treatment, and with anti-dsDNA antibodies (80U/
ml); SLE6 was a black female presenting with a renal flare,
on HCQ treatment, and with undetectable anti-dsDNA
antibodies. Because we wanted to capture the diversity of
SLE clinical manifestations, our study is not adequately
Thapa et al. Arthritis Research & Therapy  (2015) 17:132 Page 10 of 12powered to allow analysis of patient subgroups based on
flare type, laboratory parameters, or treatments.
By itself, the presence of stable, highly expanded T
cell populations in PB is not a feature indicative of a
disease state. Rather, even among healthy individuals, T
cell responses to vaccination [46] and pathogens [46, 47],
particularly against latent viruses such as human cyto-
megalovirus and Epstein-Barr virus, have been known to
occupy a significant proportion of the repertoire for de-
cades [44]. In our study, the top 50 clones represented
10.8 ±6.7 % of the repertoire in HC (vs 13.6 ±12.3 % in
SLE, P = 0.913) whereas the top 5th percentile of the
clones represented 43.2 ±6.8 % of the repertoire in HC (vs
44.7 ±11.3 % in SLE, P = 0.913) (Fig. 1f). HC repertoires
with an abundance of HECs (clone size ≥1 %) were ob-
served in three of six HC subjects (HC151, HC166 and
HC169) among whom HC151 and HC166 had the two
highest clonality scores and Gini coefficient values that
were comparable to most SLE subjects (Fig. 3a, b, c). Add-
itionally, even though the average proportion of clonally
expanded T cells differed among individuals (Figure S3, S4
in Additional file 2), the composition and relative rank of
these clones stayed remarkably stable over time (Figs. 2,
3a). Given these data, it is likely that only disease-specific
autoreactive clones within the repertoire will display ex-
pansion kinetics that correlate with disease activity. Thus,
the utility of NGS as a tool to monitor disease activity in
SLE could significantly benefit from prior knowledge of
such pathogenic clones to enable their tracking. Further
studies are warranted using sorted T cell subsets both
from blood and affected tissues simultaneously [14, 15,
41] to help pinpoint such disease-specific clones.
Multiple individuals sharing a common TCR, termed
public T cell response, has been observed during viral
infections, tumorigenesis, and in autoimmune diseases
such as multiple sclerosis, rheumatoid arthritis, aplastic
anemia, and sarcoidosis (reviewed in [48]). In SLE, the
amino acid sequences of the expanded TCR response
between individuals are largely non-overlapping. How-
ever some studies have shown recurrent T cell CDR3
motifs such as GGX in PB [6], SSG, GQG, and VRG in
kidneys [14], LXG in skin [13] or charged residues in
PB-derived anti-dsDNA inducing T helper cells [5]. In
our study, no overlap in CDR3 sequences was found be-
tween any SLE patients when the top 100 clones from
each repertoire were compared. While this suggests a
general lack of public response in PB of SLE patients,
several considerations should be made with this inter-
pretation. First, TCR repertoire is shaped by the human
leukocyte antigen (HLA) type of the individual. How-
ever, due to sample constraints, we were not able to per-
form HLA-phenotype analysis in our patients. Second,
the immense promiscuity [49] and cross-reactivity [50]
of TCRs does not preclude the presence of TCRresponses to common autoantigens between these pa-
tients. Third, the functional identity of the dominant
clones in these repertoires is largely unknown and may
mostly be represented by the individual’s response to
vaccinations and infections given that most of these
clones are stably maintained at high levels irrespective
of disease activity. In such scenarios, public TCR clones
may exist in SLE but without achieving repertoire dom-
inance. And finally, the phenomenon of epitope spread-
ing [51–53] further diversifies the TCR response from
its original epitope to newer epitopes over time. Public
responses may be more likely in the preclinical stages of
the disease when the immune response is directed to-
ward a limited set of autoantigens [54].
Despite treatments, SLE patients exhibit an unpredict-
able disease course with no reliable biomarkers to pre-
dict flare. The clinical relevance of this study has been in
its use of longitudinal samples from SLE patients with
diverse manifestations and treatment backgrounds who
flared mostly to moderate disease activity level. However,
lack of knowledge of autoantigens or the autoreactive
clones is a limiting factor and has hampered the use of
such NGS data to track disease-specific clones. In this
regard, when possible, concomitant TCR profiling from
tissue biopsies where the immune response is dominated
by fewer HECs could be performed to help pinpoint pos-
sible autoreactive clones.
Conclusions
In summary, using NGS of TCRβ, we showed that SLE
patients displayed about a twofold reduction in T cell
repertoire diversity per fixed PB volume when compared
to HC. The relative proportion of clonally expanded T
cells was higher in SLE as compared to HC, although
the difference did not reach statistical significance. Im-
portantly, in most SLE patients, longitudinal analysis
showed that diversity, the skewing of clonal distribution,
or proportion of clonal expansion in the repertoire did
not change significantly at disease flare relative to clin-
ical quiescence. Overall, these results suggest that clonal
expansions in the context of reduced repertoire may be
a defining feature of SLE, however, increases in disease
activity are not reflected with immunological changes at
the total T cell repertoire level. Nevertheless, if disease-
specific T cell clones can be identified, next-generation
sequencing may provide a powerful and high-resolution
approach to monitor pathogenic clones that may correl-
ate better with disease activity in SLE.
Additional files
Additional file 1: Table S1. Summary of TCRβ CDR3 sequencing results
from all 51 samples. Table S2. Top 50 HC clones: CDR3 sequences, rank
and frequency. Clones that show significant changes are marked in red.
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Additional file 2: Figure S1. Cumulative contributions to the total
repertoire by the top 500 clones are shown for HC (A) and SLE subjects
(B). Dotted line represents the median value. Figure S2. Differential Vβ
gene (A) and Jβ gene (B) usage between HC and SLE groups. Genes that
are differentially expressed between the two groups are indicated by
asterisk after the gene name (*, P <0.05; **, P <0.01; t test, FDR = 10 %).
Level of gene usage was calculated as a percentage of uniques. Figure
S3. Longitudinal analysis of the proportion of repertoire occupied by the
three clonal groups in SLE (top 50, >95th percentile, <95th percentile)
during quiescence (A), pre-flare (B), and flare (C). The same data is shown
in line graph form for the top 50 clones (D) and the top 5th percentile of
clones (E). Figure S4. Longitudinal analysis of the proportion of repertoire
occupied by the three clonal groups in HC (top 50, >95th percentile,
<95th percentile) during baseline (A) and at times 5 to 6 months later (B).
The same data is shown in line graph form for the top 50 clones (C) and
the top 5th percentile of clones (D).Abbreviations
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